Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)

非洲抗逆转录病毒治疗时代的卡波西肉瘤计划 (KEAAP)

• 批准号: 10598769
• 负责人: Julius David Mwaiselage
• 金额: $ 92.06万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10598769
• 关键词: AIDS related cancer; Address; Africa; Africa South of the Sahara; Bilateral; Cancer Biology; Cancer Center; Cancer Patient; Cancer Research Infrastructure; Caring; Chronic; Collaborations; Core Facility; Country; Detection; Diagnosis; Disease; Educational workshop; Ensure; Epidemic; Etiology; Fostering; Funding; Future; Goals; HIV; HIV-1; HIV/AIDS; Health Sciences; Hospitals; Human Herpesvirus 8; Human Resources; Immune response; Immunosuppression; Incidence; Individual; Kaposi Sarcoma; Lateral; Lead; Leadership; Learning; Link; Louisiana; Malignant Neoplasms; Mediating; Mentors; Molecular; Oceans; Oncology; Outcome; Pathogenesis; Pathology; Patients; Persons; Pilot Projects; Population; Positioning Attribute; Public Health; Research; Research Infrastructure; Research Personnel; Research Project Grants; Residual state; Staging; Tanzania; Teaching Hospitals; Technology Transfer; Tissues; Training; Training Activity; Training Programs; Training and Infrastructure; United States; Universities; Viral; Vision; Zambia; anticancer research; antiretroviral therapy; clinical care; health disparity populations; immune activation; low and middle-income countries; metabolome; next generation; prevent; programs; success

There are currently over 1.2 million people in Zambia and 1.7 million in Tanzania who are living with HIV/AIDS. Concomitant to the HIV epidemic, there is a high incidence of HIV/AIDS-associated malignancies (HIVAM) in these two countries. Even in this era of antiretroviral therapy (ART) Kaposi sarcoma (KS) has remained one of the most common HIVAM. This underscores a critical need for research in the context of ART-mediated changes in the HIV epidemic so that we are better equipped to diagnose, manage, and prevent KS in sub- Saharan Africa (SSA). To address this need, the overall vision of the “Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)” is to build a collaborative network between the Cancer Diseases Hospital (CDH) and University Teaching Hospitals (UTH) in Zambia, the Ocean Road Cancer Institute (ORCI) in Tanzania, and the Stanley S Scott Cancer Center at the Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO) to conduct cutting edge research that will lead to a better understanding of KS, and in parallel, continue to enhance HIVAM and non-HIVAM research capacity in Zambia and Tanzania to meet the needs of the cancer patients. KEAAP’s theme centers on the research gaps of the KS disease spectrum, from detection, to care and outcomes, to deciphering KS pathogenesis and immune response towards achieving KEAAP’s overall goal to prevent and curing the disease. KEAAP’s immediate objective is to further enhance the cancer research infrastructure in CDH/UTH and ORCI through support for interdisciplinary and bilateral KS research projects to address some of the research gaps in SSA: 1) KS diagnosis and disease staging, and linking to care; 2) changes in the immune response and metabolomes in KS patients upon treatment; and 3) identification and characterization of KSHV tissue reservoirs, and the effects of ART and HIV on these reservoirs. This proposed consortium will provide diverse training activities in the U.S., Zambia, and Tanzania to engage the next generation of low and middle income countries (LMICs) and U.S. cancer researchers, increase local expertise, and enhance the transfer of technology. KEAAP’s goal will be accomplished through the completion of three specific aims:1) Develop the cancer research infrastructure at UTH/CDH and ORCI through the establishment and enhancement of three core facilities; 2) Provide an opportunity for former Fogarty trained fellows to lead three hypothesis-driven KS research projects; 3) Develop a pipeline of next- generation U.S. and LMICs cancer researchers through a) in-country workshops, b) pilot project funding, and c) short-term U.S. and in-country training. KEAAP is high impact because it builds on successful ongoing Fogarty and NCI training programs; it will implement a cross-disciplinary and tri-lateral research and training program that are driven by our Tanzanian and Zambian collaborators with broad local support to ensure their sustainability. The lessons learned will also benefit Louisiana HIV-1 and cancer research since the state has the fifth largest population of people living with HIV, mostly among its health disparities population.

目前，赞比亚有超过120万人，坦桑尼亚有170万人患有艾滋病毒/艾滋病。 与HIV流行有关，艾滋病毒/艾滋病相关的恶性肿瘤（HIVAM）在 这两个国家。即使在这个抗逆转录病毒疗法的时代（ART）Kaposi肉瘤（KS）仍然是 最常见的Hivam。这突显了在艺术介导的背景下对研究的迫切需求 HIV流行的变化，因此我们可以更好地诊断，管理和防止KS 撒哈拉非洲（SSA）。为了满足这一需求，“ Kaposi肉瘤在艺术时代 非洲计划（KEAAP）”是在癌症疾病医院（CDH）和 赞比亚的大学教学医院（UTH），坦桑尼亚的海洋公路癌症研究所（ORCI）和 路易斯安那州立大学健康科学中心新奥尔良斯坦利的斯科特癌症中心 （lsuhsc-no）进行尖端研究，从而可以更好地理解KS，并且并行， 继续提高赞比亚和坦桑尼亚的Hivam和非Hivam研究能力，以满足 癌症患者。 KEAAP的主题集中在KS病谱的研究差距上，来自 检测，照顾和结果，破译KS发病机理和免疫反应 KEAAP预防和治愈疾病的总体目标。 KEAAP的直接目标是进一步增强 通过支持跨学科和双边KS的CDH/UTH和ORCI的癌症研究基础设施 研究项目旨在解决SSA中的一些研究差距：1）KS诊断和疾病分期，以及 链接到护理； 2）治疗后KS患者的免疫反应和代谢组发生变化； 3） KSHV组织储层的识别和表征，以及艺术和HIV对这些的影响 水库。该拟议的财团将在美国，赞比亚和坦桑尼亚提供潜水员培训活动 参与下一代低收入和中等收入国家（LMIC）和美国癌症研究人员的参与 提高本地专业知识并增强技术的传输。 KEAAP的目标将通过 完成三个特定目的的完成：1）在UTH/CDH和ORCI开发癌症研究基础设施 通过建立和增强三个核心设施； 2）为前任提供机会 Fogarty训练有素的研究员领导三个假设驱动的KS研究项目； 3）开发下一步的管道 美国和LMIC癌症的一代研究人员通过a）国内研讨会，b）试点项目资金和 C）美国短期和国内培训。 KEAAP具有很高的影响，因为它建立在成功的基础上 Fogarty和NCI培训计划；它将实施跨学科和三边研究和培训 由我们的坦桑尼亚和赞比亚合作者驱动的计划，并获得广泛的本地支持，以确保他们的 可持续性。所学的教训还将受益于路易斯安那州HIV-1和癌症研究，因为该州已有 患有艾滋病毒的人群中的第五大人口，主要是其健康分布人群。